FDA To Provide Celebrex, Iressa Regulatory Updates Before Christmas

Acting Commissioner Crawford says agency will make "some statement very soon with respect to COX-2 inhibitors in general" and Pfizer's Celebrex "in specific." FDA also will determine whether AstraZeneca's Iressa should be withdrawn or if other regulatory actions are appropriate.